Clinical and population genetic insights into primary complement component 2 (C2) deficiency: A founder variant in Ashkenazi Jews
Clinical Immunology · 2026-10 · 287 · 110758
DOI: 10.1016/j.clim.2026.110758 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Immunology, 2026-10. Verfasst von Oded Shamriz und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada (IMRIC), Faculty of Medicine, Hebrew University…. Hauptthemen laut MEDLINE: Jews, Complement C2, Founder Effect, Lupus Erythematosus, Cutaneous. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Complement component 2 deficiency (C2D) is the most common inherited complement deficiency and is associated with severe bacterial infections and autoimmunity. We describe a 14-year-old Ashkenazi Jewish boy presenting with bullous cutaneous lupus erythematosus and lupus nephritis, whose diagnosis of C2D was prompted by a family history of fatal pneumococcal meningitis in a sibling. Genetic analysis identified homozygosity for the recurrent C2 c.841_849 + 19del variant, and complement studies confirmed absent classical pathway activity and profoundly reduced C2 levels. Population analysis of approximately 33,000 exomes from the Hadassah Medical Center database demonstrated marked enrichment of the variant among Ashkenazi Jews, with an estimated carrier frequency of ∼3%, whereas the variant was rare in Mizrahi Jews and not detected among Israeli Arabs in our cohort. These findings support a founder effect in the Ashkenazi Jewish population and suggest that C2D may be substantially underdiagnosed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada (IMRIC), Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Allergy and Clinical Immunology Unit…
- Department of Dermatology, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Pathology, The Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Medical Center, Jerusalem, Israel.
- Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; Hemato-Immunology Unit, Hematology Lab and Sheba Cance…
- Hemato-Immunology Unit, Hematology Lab and Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
- Hemato-Immunology Unit, Hematology Lab and Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Department of Nephrology, Sheba Medical Center, Ramat Gan, Israel.
Zitieren
APA
Shamriz, O., Molho-Pessach, V., Benshushan, S., Simon, A. J., Orbaum-Harel, O., Askenasy, E., Slovik, M., Shaag, A., Volovelsky, O., Shimonov, A., Berkun, Y., Tal, Y., & Matza-Porges, S. (2026). Clinical and population genetic insights into primary complement component 2 (C2) deficiency: A founder variant in Ashkenazi Jews. Clinical Immunology, 287, 110758. https://doi.org/10.1016/j.clim.2026.110758
Vancouver
Shamriz O, Molho-Pessach V, Benshushan S, Simon AJ, Orbaum-Harel O, Askenasy E, et al. Clinical and population genetic insights into primary complement component 2 (C2) deficiency: A founder variant in Ashkenazi Jews. Clinical Immunology. 2026;287:110758. doi:10.1016/j.clim.2026.110758
BibTeX
@article{Shamriz2026,
author = {Shamriz, Oded and Molho-Pessach, Vered and Benshushan, Stephanie and Simon, Amos J and Orbaum-Harel, Odelia and Askenasy, Enosh and Slovik, Maya and Shaag, Avraham and Volovelsky, Oded and Shimonov, Amir and Berkun, Yacov and Tal, Yuval and Matza-Porges, Sigal},
title = {Clinical and population genetic insights into primary complement component 2 (C2) deficiency: A founder variant in Ashkenazi Jews},
journal = {Clinical Immunology},
year = {2026},
volume = {287},
pages = {110758},
doi = {10.1016/j.clim.2026.110758}
}
EUVIMED